Omnicell, Inc. (OMCL) Receives “Overweight” Rating from Cantor Fitzgerald
Omnicell, Inc. (NASDAQ:OMCL)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued on Tuesday. They currently have a $47.00 price target on the stock, up from their previous price target of $43.00. Cantor Fitzgerald’s price objective points to a potential upside of 9.68% from the company’s current price.
OMCL has been the topic of a number of other reports. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday, February 22nd. TheStreet upgraded shares of Omnicell from a “c” rating to a “b-” rating in a report on Wednesday, February 15th. CIBC increased their target price on shares of Omnicell from $43.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, April 26th. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, ValuEngine upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $46.33.
Shares of Omnicell (NASDAQ:OMCL) traded up 0.35% during trading on Tuesday, reaching $43.00. 107,043 shares of the company traded hands. The company’s market capitalization is $1.60 billion. Omnicell has a 52 week low of $30.35 and a 52 week high of $43.35. The firm’s 50 day moving average price is $41.32 and its 200-day moving average price is $37.88.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, May 4th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.36. Omnicell had a negative net margin of 1.45% and a positive return on equity of 2.66%. The firm had revenue of $150.90 million for the quarter, compared to analyst estimates of $152.63 million. During the same period in the prior year, the business posted $0.35 EPS. The business’s revenue for the quarter was down 12.3% compared to the same quarter last year. Equities analysts anticipate that Omnicell will post $1.28 EPS for the current fiscal year.
In other Omnicell news, Director James T. Judson sold 12,148 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $41.50, for a total value of $504,142.00. Following the sale, the director now directly owns 19,130 shares of the company’s stock, valued at approximately $793,895. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Randall A. Lipps sold 9,900 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $43.00, for a total transaction of $425,700.00. Following the completion of the sale, the chairman now directly owns 208,982 shares in the company, valued at $8,986,226. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 69,473 shares of company stock worth $2,869,438. 3.75% of the stock is owned by company insiders.
Several large investors have recently made changes to their positions in OMCL. Menta Capital LLC purchased a new stake in shares of Omnicell during the fourth quarter worth approximately $380,000. Champlain Investment Partners LLC increased its stake in shares of Omnicell by 21.1% in the fourth quarter. Champlain Investment Partners LLC now owns 1,599,065 shares of the company’s stock worth $54,208,000 after buying an additional 278,495 shares in the last quarter. Greenwood Capital Associates LLC increased its stake in shares of Omnicell by 0.5% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,337 shares of the company’s stock worth $350,000 after buying an additional 50 shares in the last quarter. Azimuth Capital Management LLC increased its stake in shares of Omnicell by 1.1% in the fourth quarter. Azimuth Capital Management LLC now owns 111,910 shares of the company’s stock worth $3,794,000 after buying an additional 1,225 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Omnicell during the fourth quarter worth approximately $788,000. 96.35% of the stock is currently owned by institutional investors.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.